<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>3</IssueIDStart>
          <IssueIDEnd>3</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>9</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art1">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>73503</ArticleID>
            <ArticleDOI>10.1208/aapsj070351</ArticleDOI>
            <ArticleSequenceNumber>1</ArticleSequenceNumber>
            <ArticleTitle Language="En">Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications</ArticleTitle>
            <ArticleFirstPage>E503</ArticleFirstPage>
            <ArticleLastPage>E512</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>23</Day>
              </RegistrationDate>
              <Received>
                <Year>2005</Year>
                <Month>4</Month>
                <Day>4</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>4</Month>
                <Day>29</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>3</IssueIDStart>
              <IssueIDEnd>3</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Venkatesh</GivenName>
                  <GivenName>A.</GivenName>
                  <FamilyName>Bhattaram</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Brian</GivenName>
                  <GivenName>P.</GivenName>
                  <FamilyName>Booth</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Roshni</GivenName>
                  <GivenName>P.</GivenName>
                  <FamilyName>Ramchandani</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>B.</GivenName>
                  <GivenName>Nhi</GivenName>
                  <FamilyName>Beasley</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Yaning</GivenName>
                  <FamilyName>Wang</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Veneeta</GivenName>
                  <FamilyName>Tandon</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>John</GivenName>
                  <GivenName>Z.</GivenName>
                  <FamilyName>Duan</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Raman</GivenName>
                  <GivenName>K.</GivenName>
                  <FamilyName>Baweja</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Patrick</GivenName>
                  <GivenName>J.</GivenName>
                  <FamilyName>Marroum</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Ramana</GivenName>
                  <GivenName>S.</GivenName>
                  <FamilyName>Uppoor</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Nam</GivenName>
                  <GivenName>Atiqur</GivenName>
                  <FamilyName>Rahman</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Chandrahas</GivenName>
                  <GivenName>G.</GivenName>
                  <FamilyName>Sahajwalla</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>J.</GivenName>
                  <GivenName>Robert</GivenName>
                  <FamilyName>Powell</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Mehul</GivenName>
                  <GivenName>U.</GivenName>
                  <FamilyName>Mehta</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Jogarao</GivenName>
                  <GivenName>V.</GivenName>
                  <GivenName>S.</GivenName>
                  <FamilyName>Gobburu</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>(301) 594-2109</Phone>
                  <Fax>(301) 480-3212</Fax>
                  <Email>jogarao.gobburu@fda.hhs.gov</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgName>Food and Drug Administration</OrgName>
                <OrgAddress>
                  <Street>1451 Rockville Pike, Rm 2039, HFD-860</Street>
                  <Postcode>20852</Postcode>
                  <City>Rockville</City>
                  <State>MD</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>The value of quantitative thinking in drug development and regulatory review is increasingly being appreciated. Modeling and simulation of data pertaining to pharmacokinetic, pharmacodynamic, and disease progression is often referred to as the pharmacometrics analyses. The objective of the current report is to assess the role of pharmacometrics at the US Food and Drug Administration (FDA) in making drug approval and labeling decisions. The New Drug Applications (NDAs) submitted between 2000 and 2004 to the Cardio-renal, Oncology, and Neuropharmacology drug products divisions were surveyed. For those NDA reviews that included a pharmacometrics consultation, the clinical pharmacology scientists ranked the impact on the regulatory decision(s). Of about a total of 244 NDAs, 42 included a pharmacometrics component. Review of NDAs involved independent, quantitative evaluation by FDA pharmacometricians, even when such analysis was not conducted by the sponsor. Pharmacometric analyses were pivotal in regulatory decision making in more than half of the 42 NDAs. Of the 14 reviews that were pivotal to approval related decisions, 5 identified the need for additional trials, whereas 6 reduced the burden of conducting additional trials. Collaboration among the FDA clinical pharmacology, medical, and statistical reviewers and effective communication with the sponsors was critical for the impact to occur. The survey and the case studies emphasize the need for early interaction between the FDA and sponsors to plan the development more efficiently by appreciating the regulatory expectations better.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>regulatory decisions</Keyword>
              <Keyword>modeling</Keyword>
              <Keyword>simulation</Keyword>
              <Keyword>FDA</Keyword>
              <Keyword>dose-response</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: October 7, 2005</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_73503.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SC</Initials>
                    <FamilyName>Olson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Bockbrader</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Boyd</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis</ArticleTitle>
                  <JournalTitle>Clin Pharmacokinet</JournalTitle>
                  <VolumeID>38</VolumeID>
                  <FirstPage>449</FirstPage>
                  <LastPage>459</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10843462</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.2165/00003088-200038050-00005</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXktFGqsb8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Olson SC, Bockbrader H, Boyd RA, et al. Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 2000;38:449–459.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>BG</Initials>
                    <FamilyName>Reigner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PE</Initials>
                    <FamilyName>Williams</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IH</Initials>
                    <FamilyName>Patel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Steimer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Peck</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Brummelen</FamilyName>
                    <Particle>van</Particle>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche</ArticleTitle>
                  <JournalTitle>Clin Pharmacokinet</JournalTitle>
                  <VolumeID>33</VolumeID>
                  <FirstPage>142</FirstPage>
                  <LastPage>152</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9260036</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.2165/00003088-199733020-00005</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXlsVyitLY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C, van Brummelen P. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1997;33:142–152.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>EI</Initials>
                    <FamilyName>Ette</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Miller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WR</Initials>
                    <FamilyName>Gillespie</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1997</Year>
                  <ChapterTitle Language="En">The Population Approach: FDA Experience</ChapterTitle>
                  <BibEditorName>
                    <Initials>LP</Initials>
                    <FamilyName>Balant</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>L</Initials>
                    <FamilyName>Aarons</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose</BookTitle>
                  <PublisherName>Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research</PublisherName>
                  <PublisherLocation>Brussels</PublisherLocation>
                </BibChapter>
                <BibUnstructured>Ette EI, Miller R, Gillespie WR, et al. The Population Approach: FDA Experience. In Balant LP and Aarons L, eds.<Emphasis Type="Italic">The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose</Emphasis>. Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research, Brussels, 1997.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>WS</Initials>
                    <FamilyName>Colucci</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>U</Initials>
                    <FamilyName>Elkayam</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DP</Initials>
                    <FamilyName>Horton</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group</ArticleTitle>
                  <JournalTitle>N Engl J Med</JournalTitle>
                  <VolumeID>343</VolumeID>
                  <FirstPage>246</FirstPage>
                  <LastPage>253</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10911006</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJM200007273430403</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXlvVSmtLw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 2000;343:246–253.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibUnstructured>Nesiritide. Center for Drug Evaluation and Research, United States Food and Drug Administration. Available at: http://www.fda.gov/ohrms/dockets/ac/cder99t.htm#Cardiovascular%20and% 20Renal%20Drugs/3490t2.pdf. Accessed on March 21, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <InstitutionalAuthorName>Publication Committee for the VMAC Investigators</InstitutionalAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial</ArticleTitle>
                  <JournalTitle>JAMA</JournalTitle>
                  <VolumeID>287</VolumeID>
                  <FirstPage>1531</FirstPage>
                  <LastPage>1540</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1001/jama.287.12.1531</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.<Emphasis Type="Italic">JAMA</Emphasis>. 2002;287:1531–1540.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibUnstructured>Apomorphine, Center for Drug Evaluation and Research, US Food and Drug Administration. Available at: http://www.fda.gov/cder/foi/nda/2004/21-264_Apokyn.htm Accessed on March 21, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Chang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Green</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Beitz</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Renal failure with the use of zoledronic acid</ArticleTitle>
                  <JournalTitle>N Engl J Med</JournalTitle>
                  <VolumeID>349</VolumeID>
                  <FirstPage>1676</FirstPage>
                  <LastPage>1679</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14573746</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJM200310233491721</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXosFakurw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 2003;349:1676–1679.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Booth</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Rahman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Ibrahim</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">A population pharmacokinetic model for zoledronic acid (ZOMETA) in patients with bone metastases</ArticleTitle>
                  <JournalTitle>Am Soc Clin Pharmacol Ther</JournalTitle>
                  <VolumeID>PIII–20</VolumeID>
                  <FirstPage>67</FirstPage>
                  <LastPage>67</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0009-9236(03)90605-9</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Booth B, Rahman A, Ibrahim A, et al. A population pharmacokinetic model for zoledronic acid (ZOMETA) in patients with bone metastases.<Emphasis Type="Italic">Am Soc Clin Pharmacol Ther</Emphasis>. 2003;(PIII–20):67.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibUnstructured>Zoledronic Acid Label: Center for Drug Evaluation and Research, US Food and Drug Administration. Available at: www.fda.gov/cder/foi/label/2005/021223s009.0101bl.pdf. Accessed March 21, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibUnstructured>Zometa (Zoledronic Acid): Center for Drug Evaluation and Research, US, Food and Drug Administration. Available at: http://www.fda/gov/medwatch/SAFETY/2005/safety05.htm#Zometa. Accessed March 29, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibUnstructured>Busulfan, Center for Drug Evaluation and Research, United States Food and Drug Administration. Available at: http://www.fda.gov/cder/foi/nda/2002/20-954S004_Busulfex.htm Accessed March 21, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Slattery</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Clift</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CD</Initials>
                    <FamilyName>Buckner</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation</ArticleTitle>
                  <JournalTitle>Blood</JournalTitle>
                  <VolumeID>89</VolumeID>
                  <FirstPage>3055</FirstPage>
                  <LastPage>3060</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9108427</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXisFCls70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.<Emphasis Type="Italic">Blood</Emphasis>. 1997;89:3055–3060.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LB</Initials>
                    <FamilyName>Grochow</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RJ</Initials>
                    <FamilyName>Jones</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RB</Initials>
                    <FamilyName>Brundrett</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1989</Year>
                  <ArticleTitle Language="En">Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation</ArticleTitle>
                  <JournalTitle>Cancer Chemother Pharmacol</JournalTitle>
                  <VolumeID>25</VolumeID>
                  <FirstPage>55</FirstPage>
                  <LastPage>61</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2591002</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/BF00694339</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK3c%2FnsFejtw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.<Emphasis Type="Italic">Cancer Chemother Pharmacol</Emphasis> 1989;25:55–61.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>DeMagalhaes-Silverman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EJ</Initials>
                    <FamilyName>Bloom</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Donnenberg</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies</ArticleTitle>
                  <JournalTitle>Bone Marrow Transplant</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>329</FirstPage>
                  <LastPage>333</LastPage>
                  <Occurrence Type="PID">
                    <Handle>8704682</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK283ktlyluw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>DeMagalhaes-Silverman M, Bloom EJ, Donnenberg A, et al. Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies.<Emphasis Type="Italic">Bone Marrow Transplant</Emphasis>. 1996;17:329–333.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibUnstructured>Betapace (Sotalol Hydrochloride). Center for Drug Evaluation and Research, United States Food and Drug Administration. Available at:http://www.fda.gov/cder/foi/nda/2001/19-865s10_Betapace.htm. Accessed March 21, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Shi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TM</Initials>
                    <FamilyName>Ludden</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AP</Initials>
                    <FamilyName>Melikian</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MR</Initials>
                    <FamilyName>Gastonguay</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PH</Initials>
                    <FamilyName>Hinderling</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia</ArticleTitle>
                  <JournalTitle>J Pharmacokinet Pharmacodyn</JournalTitle>
                  <VolumeID>28</VolumeID>
                  <FirstPage>555</FirstPage>
                  <LastPage>575</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11999292</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1014412521191</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XjsFSrtrg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia.<Emphasis Type="Italic">J Pharmacokinet Pharmacodyn</Emphasis>. 2001;28:555–575.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibUnstructured>Gobburu J. Could an, EOP2A meeting shorten drug development time? Available at: http://www.fda.gov/ohrms/dockets/ac/03/slides/ 3998S1_06_Gobburu_files/frame.htm. Accessed March 21, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Kola</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Landis</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Can the pharmaceutical industry reduce, attrition rates?</ArticleTitle>
                  <JournalTitle>Nat Rev Drug Discov</JournalTitle>
                  <VolumeID>3</VolumeID>
                  <FirstPage>711</FirstPage>
                  <LastPage>715</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15286737</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/nrd1470</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXmtVOhtLs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kola I, Landis J. Can the pharmaceutical industry reduce, attrition rates?<Emphasis Type="Italic">Nat Rev Drug Discov</Emphasis>. 2004;3:711–715.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibUnstructured>Advisory Committee for Pharmaceutical Science, Clinical Pharmacology Subcommittee, US Food and Drug Administration. Available at: http://www.fda.gov/ohrms/dockets/ac/03/slides/ 3998s1.htm. Accessed March 29, 2005.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibUnstructured>Challenge and Oppurtunity on the Critical Path to New Medical Products, United States Food and Drug Administration. Available at: http://www.fda.gov/oc/initiatives/criticalpath/. Accessed March 21, 2005.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
